SeaStar Medical Holding Corp — SEC Form D Filing
SeaStar Medical Holding Corp filed an SEC Form D on October 8, 2026, reporting $3.30M raised in Other Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 8, 2026
- Amount reported
- $3.30M
- Round stage
- Growth funding raised via private placement to support the commercial deployment of its approved pediatric therapy and advance adult clinical trials.
- Industry
- Other Health Care
- Website
- https://seastarmedical.com
What the company does
Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Hyperinflammation and dysregulated immune responses in critically ill patients cause severe organ failure and high mortality rates during acute kidney injury.
Solution
SeaStar Medical Holding develops the Selective Cytopheretic Device to selectively neutralize hyperactive inflammatory cells in extracorporeal blood circuits during continuous renal replacement therapy.
Why now
Recent FDA approval of QUELIMMUNE for pediatric acute kidney injury creates an immediate commercialization opportunity for targeted immunomodulatory critical care devices.
Source: SEC EDGAR Form D filing